Conjugated Linoleic Acid in Obese Women (CLA)

August 18, 2015 updated by: Edilson Serpeloni Cyrino, Universidade Estadual de Londrina

Effect of Conjugated Linoleic Acid Associated With Aerobic Exercise on Body Fat and Lipid Profile in Obese Women: A Randomized, Double-blinded and Placebo-controlled Trial

In this trial, the investigators analyzed the effects of eight weeks of CLA supplementation associated with aerobic exercise on body fat and lipid profile in obese women.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aim of this investigation was to analyze the effects of eight weeks of CLA supplementation associated with aerobic exercise on body fat and lipid profile in obese women. The investigators performed a randomized, double-blinded and placebo-controlled trial with 28 obese women who received 3.2 g/d of CLA or 4 g/d of olive oil (placebo group) while performing an 8-week protocol of aerobic exercise. Dietary intake (food record), body fat (DXA) and biochemical analysis (blood sample) were assessed before and after the intervention period.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Paraná
      • Londrina, Paraná, Brazil, 86.057-970
        • Universidade Estadual de Londrina

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Had no signs or symptoms of disease
  • No orthopedic injuries
  • Must be inactive or moderately active (defined as performing any type of physical exercise less than twice a week)
  • Must be non-smokers
  • Must be free from the use of ergogenic aids
  • Had no metabolic disorders or chronic degenerative diseases
  • Not use drug therapy for body mass loss.

Exclusion Criteria:

  • Had frequency to training sessions below 85% of the total sessions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Aerobic exercise associated with CLA
CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
Dietary supplement: CLA
CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
Placebo Comparator: Aerobic exercise
Placebo group received 4 g/day of olive oil.
Behavioral: Placebo
Placebo group received 4 g/day of olive oil. Aerobic exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body fat
Time Frame: 8 weeks
Dual-energy X-ray absorptiometry
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total cholesterol
Time Frame: 8 weeks
Blood analysis
8 weeks
Triglycerides
Time Frame: 8 weeks
Blood analysis
8 weeks
High-density lipoprotein
Time Frame: 8 weeks
Blood analysis
8 weeks
Low-density lipoprotein
Time Frame: 8 weeks
Estimated by Friedewald formula
8 weeks
Trunk fat
Time Frame: 8 weeks
Dual-energy X-ray absorptiometry
8 weeks
Arm fat
Time Frame: 8 weeks
Dual-energy X-ray absorptiometry
8 weeks
Leg fat
Time Frame: 8 weeks
Dual-energy X-ray absorptiometry
8 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass
Time Frame: 8 weeks
Urano, model PS 180
8 weeks
Maximum oxygen uptake
Time Frame: 8 weeks
incremental treadmill test
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universidade Estadual de Londrina

Investigators

  • Study Chair: Edilson Cyrino, PhD, Universidade Estadual de Londrina

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2007

Primary Completion (Actual)

June 1, 2007

Study Completion (Actual)

July 1, 2007

Study Registration Dates

First Submitted

August 4, 2015

First Submitted That Met QC Criteria

August 18, 2015

First Posted (Estimate)

August 19, 2015

Study Record Updates

Last Update Posted (Estimate)

August 19, 2015

Last Update Submitted That Met QC Criteria

August 18, 2015

Last Verified

August 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ESCyrino

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on CLA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe